Scots HTA approves four products, but more disappointment for Roche's Perjeta
This article was originally published in Scrip
Executive Summary
Scotland's health technology assessment agency, the Scottish Medicines Consortium (SMC), has given the go-ahead for four products to be used on NHS Scotland, including a first HTA nod for Lundbeck's alcohol dependency drug Selincro (nalmefene). Unfortunately for Roche, however, the SMC was not moved to recommend breast cancer drug Perjeta (pertuzumab), a further blow after NICE too rejected the product. Roche has accused the Scottish system of being "not fit for purpose."